
Browsing restrictions can be lifted for a fee.
-1.76%
Cvrx, inc.
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Cvrx, inc. (CVRX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CVRX's short-term business performance and financial health. For the latest updates on CVRX's earnings releases, visit this page regularly.
According to the latest financial report, Cvrx, inc. (CVRX) reported an Operating Profit of -11.18M with an Operating Margin of -69.8% this period, representing a decline of 8.86% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Cvrx, inc. (CVRX) announced revenue of 16.02M, with a Year-Over-Year growth rate of 4.45%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, Cvrx, inc. (CVRX) held Total Cash and Cash Equivalents of 75.71M, accounting for 0.72 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Cvrx, inc. (CVRX) did not achieve the “three margins increasing” benchmark, with a gross margin of 86.3%%, operating margin of -69.8%%, and net margin of -74.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CVRX's profit trajectory and future growth potential.
According to the past four quarterly reports, Cvrx, inc. (CVRX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.45. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Cvrx, inc. (CVRX)'s Free Cash Flow (FCF) for the period is -9.83M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 21.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Cvrx, inc. (CVRX) has a Price-To-Earnings (PE) ratio of -2.44 and a Price/Earnings-To-Growth (PEG) ratio of 0.64. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.